Urgent

Breast lump — triple assessment

breast lump · GI / Surgical
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Any discrete breast lump requires triple assessment: clinical examination, imaging (mammography and/or ultrasound) and tissue biopsy, to confidently distinguish benign disease from breast cancer.

Red flags

  • Hard, irregular, fixed or tethered lump
  • Skin dimpling, peau d'orange or nipple retraction
  • Bloody single-duct nipple discharge
  • Axillary lymphadenopathy
  • Inflammatory skin changes (inflammatory breast cancer)

Assessment

Differential diagnosis

  • Breast carcinoma
  • Fibroadenoma
  • Breast cyst
  • Fat necrosis
  • Phyllodes tumour
  • Duct ectasia / periductal mastitis
  • Lipoma

Investigations

  • Clinical breast and axillary examination
  • Bilateral mammography (typically age >40) and/or breast ultrasound (younger women)
  • Core needle biopsy (preferred) or fine-needle aspiration
  • Axillary ultrasound +/- node biopsy
  • Breast MRI in selected cases (dense breasts, lobular cancer, implants)
  • Receptor status (ER/PR/HER2) and grade on biopsy

Management

  • Take a full history including risk factors, family history and nipple/skin changes
  • Examine both breasts and axillae systematically
  • Refer on a suspected-cancer pathway for any suspicious lump or red-flag feature
  • Arrange age-appropriate imaging (ultrasound in younger, mammography plus ultrasound in older women)
  • Assign imaging a level of suspicion and biopsy indeterminate/suspicious lesions
  • Obtain core biopsy for histology and receptor status
  • Correlate all three components (concordance); re-investigate if discordant
  • Aspirate simple symptomatic cysts; biopsy complex cysts
  • Reassure and discharge concordant benign lesions (e.g. simple fibroadenoma/cyst)
  • Refer confirmed malignancy to the breast MDT for staging and treatment planning
  • Arrange genetic referral if strong family history
  • Provide written results and clear safety-netting

Drugs & doses

Local anaesthetic (lidocaine 1%) for biopsy
Analgesia (paracetamol/NSAID) for procedure discomfort
Neoadjuvant/adjuvant systemic therapy for confirmed cancer per oncology
Endocrine therapy (e.g. tamoxifen/aromatase inhibitor) for ER-positive disease
Anti-HER2 therapy (trastuzumab) for HER2-positive disease

Disposition

Refer on a 2-week-wait breast pathway for one-stop triple assessment; benign concordant lesions discharged, confirmed cancers to the breast MDT.

Complications & pitfalls

  • Delayed cancer diagnosis from false reassurance
  • Biopsy haematoma/infection
  • Patient anxiety
  • Missed malignancy in discordant results

Exam pearls

  • Concordance of all three components is essential — act on the most suspicious result
  • A discrete new lump in any woman warrants triple assessment regardless of age
  • Ultrasound is first-line imaging in women under ~40; mammography is added in older women
  • Inflammatory breast cancer can mimic mastitis — a non-resolving 'infection' needs biopsy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.